# Agilent Technologies account plan

> Agilent Technologies sells lab instruments, software, services, consumables and CDMO capacity; FY2025 revenue $6,948 million, about 18,200 staff.

## At a glance

Agilent Technologies supplies instruments, software, services and consumables for the whole laboratory workflow, plus a specialty CDMO, to pharma and biopharma, diagnostics and clinical labs, chemicals and advanced materials, environmental, food, and academic and government customers. It sells mainly through a direct sales force, with distributors and e-commerce, and runs R&D and manufacturing in the United States, Europe and Asia Pacific. In FY2025 (year to October 31, 2025) net revenue was $6,948 million, up 7%, and net income $1,303 million; the United States accounted for $2,342 million and China including Hong Kong for $1,224 million. Headcount was about 18,200 at July 31, 2026. Padraig McDonnell has been CEO since May 2024.

## Business units

- **Agilent CrossLab** (about 42% of FY2025 revenue ($2,908 million)): Services (repair, maintenance, compliance, consulting), mostly vendor-neutral consumables such as GC and LC columns, OpenLab software and lab automation, sold to about 59,700 customers. It is the most profitable segment (32.5% operating margin in FY2025) and grew 6% in Q3 FY2026 to $786 million. Led by Angelica Reimann.
- **Life Sciences and Diagnostics Markets** (about 39% of FY2025 revenue ($2,726 million)): Liquid chromatography and LC/MS, cell analysis, pathology, companion diagnostics, genomics and the specialty CDMO, now called Agilent Advanced Therapeutics (oligonucleotide APIs and BIOVECTRA). Revenue grew 11% in FY2025 and 11% in Q3 FY2026 to $746 million, including the Biocare acquisition. Led by Simon May.
- **Applied Markets** (about 19% of FY2025 revenue ($1,314 million)): Gas chromatography, GC-MS, atomic and molecular spectroscopy, vacuum technology and remarketed instruments for chemicals and advanced materials, environmental and forensics, food and pharma. Revenue rose 1% in FY2025, then 7% in Q3 FY2026 to $346 million. Led by Mike Zhang.

## Strategic priorities

- **Ignite transformation**: Ignite, announced in late 2024, started with strategic pricing, procurement and tariff mitigation; pricing delivered about 200 basis points in Q3 FY2026, past the initial target of more than 100 basis points.
- **Long-range growth targets**: The long-range plan aims for 5 to 7% core revenue growth a year and double-digit EPS growth.
- **Pharma and reshoring**: Management sizes the pharma reshoring opportunity at about $1 billion through 2030 and expects to win at least one third; reshoring orders came from five of the top 10 pharma companies in Q3 FY2026.
- **Advanced Therapeutics capacity**: Expanding nucleic acid therapeutics manufacturing in Frederick, Colorado; Train C should generate revenue next spring, with 75% of available FY27 capacity under purchase orders.
- **Software, automation and AI**: Building software and informatics, lab automation and a digital-lab ecosystem; an enterprise AI strategy runs with OpenAI and BCG X and an Agilent AI Center of Excellence.
- **Instrument replacement and new products**: Riding the LC and GC replacement cycle with launches such as the 9500 triple quad ICP-MS, the 8890B and 8860B GCs and the Altura column family.

## Latest results

In Q3 fiscal 2026 (quarter to July 31, 2026) net revenue was $1,878 million, up 8% with no currency impact, and nine-month revenue $5,511 million, also up 8%. All three segments and all regions grew; pharma grew 12% and China 9%. GAAP operating margin rose to 23.6% from 20.7% a year earlier, with IEEPA tariff refunds adding about 1 point, and Q3 net income was $362 million. Agilent raised FY2026 guidance to revenue of $7.49 to $7.51 billion (core growth 5.8% to 6%) and EPS of $6.18 to $6.21, with capex of about $450 million.

## Investments and deals

- **Biocare acquisition**: Acquired Biocare (BC Midco I) on June 24, 2026 for $950 million net to expand pathology, funded partly by $600 million of 4.90% senior notes due 2032.
- **BIOVECTRA acquisition**: Bought BIOVECTRA on September 20, 2024 for $915 million in cash, adding microbial fermentation, bioreagents and highly potent APIs to the CDMO.
- **Frederick, Colorado capacity**: Capex was $407 million in FY2025; about $450 million is expected in FY2026, mainly for advanced therapeutics capacity in Frederick, Colorado.
- **Restructuring plans**: The FY25 plan now targets about $90 million to $95 million of annual savings; a new FY26 plan carries a $15 million charge and about $30 million to $35 million of annual savings.
- **Capital return**: Buybacks of $295 million in the first nine months of FY2026, with about $1,654 million left under the 2024 program, and a quarterly dividend of $0.255 per share.

## Challenges and risks

- **Tariffs and trade**: Higher tariffs and shipping costs compressed FY2025 margins; IEEPA refund claims are filed but their timing is uncertain, and U.S.-China relations remain a named risk.
- **Academic and government spending**: Academia and Government was the only end market to decline in FY2025 ($540 million) and fell to $128 million in Q3 FY2026, with U.S. federal funding a named risk.
- **Rising tax rate**: Pillar Two top-up taxes lifted the Q3 FY2026 effective tax rate to 18.5% from 8.2%.
- **Competition and regulation**: Agilent competes with Thermo Fisher, Danaher, Waters, Shimadzu and others, and must comply with FDA and EU IVDR rules.
- **Inventory and supply**: Inventory days on hand rose to 120 at July 31, 2026 (107 a year earlier) on strategic purchases to mitigate tariff risk and secure supply.

## What leadership says

> "make no mistake our extraordinary q3 results are no accident nor are they purely a function of improving end markets" — Padraig McDonnell, President and CEO, Q3 fiscal 2026 earnings call, August 26, 2026

> "about 1 billion through 2030, and we expect to at least win one third of that" — Padraig McDonnell, President and CEO, On pharma reshoring, Q3 fiscal 2026 earnings call, August 26, 2026

> "We are not aiming to be a generalist CDMO. We are building a specialized, high-capability business in strategic swim lanes." — Padraig McDonnell, Chief Executive Officer, GBR US Life Sciences 2025 interview

> "We have large M&A ambitions. BIOVECTRA is just the beginning." — Padraig McDonnell, President and CEO, GBR US Life Sciences 2025 interview


## Where a supplier can help

- **Capacity build-out in Colorado**: The Frederick, Colorado advanced therapeutics expansion and Train C start-up create needs for GMP equipment, engineering, validation and staffing suppliers.
- **Integrating Biocare**: The Biocare pathology acquisition calls for integration support in systems, supply chain and commercial operations within Life Sciences and Diagnostics Markets.
- **Ignite pricing and procurement**: Ignite's focus on pricing, procurement and tariff mitigation opens doors for sourcing, pricing analytics and supply chain tools that support margin goals.
- **AI and digital lab**: The enterprise AI strategy and digital-lab ecosystem point to demand for data, connectivity and automation partners that can show clear impact.
- **Reshoring demand**: Pharma reshoring orders give suppliers of lab installation, compliance and service capacity a way to support Agilent's push to win a share of that opportunity.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Form 10-K for the fiscal year ended October 31, 2025](https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/a-20251031.htm)

Annual report · 2025-12-22

- Agilent Technologies is a global leader in life sciences, diagnostics and applied markets, selling instruments, software, services and consumables for the entire laboratory workflow; about 18,100 employees at October 31, 2025 (7,100 Americas, 4,400 Europe, 6,600 Asia Pacific).
- FY2025 (year to October 31, 2025): net revenue $6,948 million, up 7% (no currency impact); BIOVECTRA contributed about 2 percentage points. Net income $1,303 million; operating margin 21.3% (down 2 points); gross margin 52.4%.
- Three segments since a November 2024 reorganisation: Life Sciences and Diagnostics Markets ($2,726 million, +11%), Agilent CrossLab ($2,908 million, +6%, the services/consumables/software engine, 32.5% operating margin) and Applied Markets ($1,314 million, +1%).
- End markets: Pharmaceutical and Biopharmaceutical $2,507 million is the largest, then Chemicals and Advanced Materials $1,561 million, Diagnostics and Clinical $1,029 million; Academia and Government ($540 million) was the only one to decline. United States $2,342 million, China including Hong Kong $1,224 million.
- Higher tariffs and shipping costs, an unfavorable mix (lower-margin specialty CDMO) and higher wages compressed margins; Agilent expects to substantially mitigate the tariff impact during fiscal 2026 through supply chain optimization, targeted pricing and cost efficiency.
- Investment: capex $407 million in FY2025 and about $500 million planned for FY2026, mainly to expand nucleic acid therapeutics manufacturing capacity in Frederick, Colorado; BIOVECTRA was bought in September 2024 for $915 million.
- Capital return: $425 million of buybacks and $282 million of dividends in FY2025; about $1.9 billion left under the 2024 repurchase program. FY25 restructuring plan: $81 million charge, $75 million to $80 million of expected annual savings.
- Leadership: Padraig McDonnell CEO since May 2024; Adam Elinoff CFO since November 2025 (ex-Amgen); segment presidents Simon May (LDM), Angelica Reimann (CrossLab), Mike Zhang (Applied Markets); Jonah Kirkwood Chief Commercial Officer.
- Key risks named: customers' capital spending and government funding (U.S. federal funding under a continuing resolution), tariffs and U.S.-China trade, FDA and EU IVDR regulation, acquisitions integration, and competition from Thermo Fisher, Danaher, Waters, Shimadzu and others.

### [Form 10-Q for the quarter ended July 31, 2026 (Q3 fiscal 2026)](https://www.sec.gov/Archives/edgar/data/1090872/000109087226000064/a-20260731.htm)

Interim report · 2026-09-01

- Q3 fiscal 2026 (quarter to July 31, 2026): net revenue $1,878 million, up 8% (no currency impact); nine months $5,511 million, up 8% (2 points favorable currency). Growth came from all segments and all regions.
- Q3 income from operations $444 million (+23%), operating margin 23.6% (20.7% a year earlier), gross margin 55.5%; tariff refunds under IEEPA contributed about 1 point of operating margin in the quarter. Q3 net income $362 million.
- Segments in Q3: Life Sciences and Diagnostics Markets $746 million (+11%), Agilent CrossLab $786 million (+6%, operating margin 34.3%), Applied Markets $346 million (+7%, operating margin 24.9%).
- Q3 end markets: Pharmaceutical and Biotechnology $707 million (from $629 million), Chemicals and Advanced Materials $430 million, Diagnostics and Clinical $284 million; Academia and Government fell to $128 million.
- Acquired Biocare (BC Midco I) on June 24, 2026 for $950 million net, expanding the pathology portfolio; funded partly by $600 million of 4.90% senior notes due 2032.
- The specialty CDMO was renamed Agilent Advanced Therapeutics; capex of about $450 million is expected for the year, mainly for advanced therapeutics capacity in Frederick, Colorado.
- New FY26 restructuring plan to optimize the management structure: $15 million charge, about $30 million to $35 million of annual savings; the FY25 plan's expected savings rose to about $90 million to $95 million.
- Customer capital budget availability "has largely normalized"; tariffs and the Middle East conflict remain dynamic but their cost impact was mitigated. Headcount about 18,200.

### [Agilent Q3 fiscal 2026 earnings call transcript](https://www.earningswhispers.com/transcript/A/Q32026)

Executive talk · Padraig McDonnell, President and Chief Executive Officer · 2026-08-26

- Q3 FY2026 revenue $1.88 billion, core growth 7.3%, 140 basis points above the top of guidance; operating margin 27.2% excluding a $20 million tariff-refund benefit (28.3% including it); EPS $1.56 ex-refund, up 14%.
- Pharma grew 12% (9% excluding CDMO); the Advanced Therapeutics division (NASD and BIOVECTRA) grew nearly 30%; GLP-1 business more than 70% growth; China grew 9% against a flat expectation.
- FY2026 guidance raised: revenue $7.49 to $7.51 billion, core growth 5.8% to 6%; EPS $6.18 to $6.21 ($6.12 to $6.15 ex-refund, 10% growth at the midpoint); capex about $450 million.
- Ignite operating system: strategic pricing delivered about 200 basis points in Q3, past the initial full-year target of more than 100 basis points; AI partnership with OpenAI and BCG X and an Agilent AI Center of Excellence.
- Pharma reshoring: opportunity sized at about $1 billion through 2030, of which Agilent expects to win at least one third; reshoring orders from five of the top 10 pharma companies in Q3; revenue from fiscal 2027.
- Product launches: 9500 triple quad ICP-MS (funnel above $60 million), 8890B and 8860B GCs (orders more than 2x expectations), Altura columns; Train C CDMO capacity to start revenue next spring, with 75% of FY27 available capacity under POs.
- Semiconductor is about 3% to 4% of Agilent revenue; Biocare contributed $10 million in Q3 and about $23 million is expected in Q4.

### [Igniting Customer-Centric Growth: A Conversation With Padraig McDonnell Of Agilent Technologies](https://www.asianscientist.com/2025/08/sponsored-feature/agilent-technologies-ignite-transformation/)

Executive talk · Padraig McDonnell, President and Chief Executive Officer · 2025-08-28

- Sponsored Asian Scientist feature (August 2025) in which CEO Padraig McDonnell explains the Ignite transformation and Singapore's role for Agilent.
- Ignite is "a company-wide transformation designed to help us scale more effectively and serve customers better", with a strategy "centered on markets and customers, not just products".
- Long-range plan: 5 to 7% core revenue growth a year and double-digit EPS growth; Ignite aims to simplify global processes, reduce complexity and build a more agile value chain.
- Customer promise: shorter lead times, consistency and quality, faster product launches and co-innovation (e.g. PFAS analysis, biopharma workflows).
- Singapore: over 600 scientists, engineers and other staff and a 172,000 square foot facility; S$85 million invested in 2017; S$38 million translational R&D hub with NUS Medicine and NUH launched in 2019.
- Digital lab: AI-driven insights across data, instruments, lab environment and enterprise; four smart factories recognized by the World Economic Forum.
- Five-year vision: more customer-centric, invest in innovation organically and through M&A, expand into high-growth adjacencies, more automation and software.

### [Agilent Technologies Interview - US Life Sciences 2025 (GBR)](https://projects.gbreports.com/us-life-sciences-2025/agilent-technologies-interview)

Executive talk · Padraig McDonnell, Chief Executive Officer

- Interview of CEO Padraig McDonnell for the GBR "US Life Sciences 2025" report, on Agilent's strategy shift, innovation, biopharma/CDMO and AI.
- Strategy built on four areas: portfolio expansion and innovation, high-growth segments, lab productivity, and software and informatics; enablers include a unified commercial organization, a digital ecosystem and the IGNITE transformation, "the biggest change in 25 years".
- Innovation: the Infinity Tree LC platform boosts lab productivity by 10-20%; collaboration with ABB Robotics on automated labs; R&D shifting to asymmetric investments in the highest-growth areas.
- CDMO: US$750 million invested in oligonucleotide manufacturing in Colorado, then the US$1 billion BIOVECTRA acquisition; "We are not aiming to be a generalist CDMO."
- Emerging areas: cell and gene therapy, large molecules, proteomics and spatial biology.
- AI: two manufacturing sites won World Economic Forum Global Lighthouse Awards; SixSense acquisition enables predictive maintenance; "The key is focus".
- M&A: "We have large M&A ambitions. BIOVECTRA is just the beginning."

## Questions about Agilent Technologies

### What does Agilent Technologies do?

Agilent sells laboratory instruments, software, services and consumables, and runs a specialty CDMO, for pharma, diagnostics, chemicals, environmental, food and academic labs. It is organised in three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets.

### What is Agilent's revenue?

Net revenue was $6,948 million in FY2025 (year to October 31, 2025), up 7%. For FY2026 Agilent guides to $7.49 to $7.51 billion.

### How many employees does Agilent have?

About 18,200 at July 31, 2026, up from about 18,100 at October 31, 2025, mainly due to the Biocare acquisition.

### Who leads Agilent Technologies?

Padraig McDonnell has been President and CEO since May 2024; Adam Elinoff has been CFO since November 2025.

### What is Agilent's strategy?

Agilent runs the Ignite transformation, targets 5 to 7% core revenue growth a year and double-digit EPS growth, and invests in advanced therapeutics capacity, pathology, software and AI, and M&A.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
